



Curriculum Vitae

Personal information Gerard Ronda Roca

Work experience

- Start date: January 2024
 - End date: Present
 - **Position held: External expert**
 - **Employer: Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)**
 - Country: Spain
 - Main activities: Preparation of Therapeutic Positioning Reports
-
- Start date: May 2022
 - End date: Present
 - **Position held: Clinical Pharmacologist medical resident**
 - **Employer: Hospital Universitario Puerta de Hierro Majadahonda - Servicio Madrileño de Salud**
 - Country: Spain
 - Main Activities: Preparation of various assessment reports (therapeutic consultation, drug information, clinical advisor, etc), pharmacovigilance, pharmacoepidemiology, Clinical trial monitoring and management, investigator's assistance. Residents' representative at the Technical and Clinical Board. Teaching collaborator at the Faculty of Medicine.

Education and training

- Start date: December 2025
 - End date: Present
 - Degree or qualification: University Expert Diploma in Statistics Applied to Health Sciences
 - Institution: Universidad Nacional de Educación a Distancia (UNED)
 - Country: Spain
 - Subjects/Skills covered: Statistical concepts and methods related to Health Sciences, as well as their practical application using computer-based tools.
-
- Start date: January 2025
 - End date: July 2025
 - Degree or qualification: University Expert Diploma in Evaluation of Medicines and Health Technologies within the National Health System
 - Institution: Universidad Nacional de Educación a Distancia (UNED)
 - Country: Spain
 - Subjects/Skills covered: Knowledge of the methods used for the evaluation of medicines and health technologies within the Spanish National Health System.
 - Currently in the process of extension to a University Expert Diploma (advanced level)
-
- Start date: October 2024
 - End date: Present
 - Degree or qualification: PhD
 - Institution: Universitat Autònoma de Barcelona (UAB)
 - Country: Spain
 - Subjects/Skills covered: Doctoral thesis "Automated personalised information support to shared decision-making in patients receiving non-curative treatments for colorectal cancer"
-
- Start date: September 2023
 - End date: October 2024
 - Degree or qualification: Master's degree
 - Institution: Universidad Internacional de La Rioja (UNIR)
 - Country: Spain
 - Subjects/Skills covered: Healthcare systems organization and governance, Health policy and strategic planning, Healthcare quality management and patient safety, Health economics and resource allocation, Leadership and management in healthcare organizations, Decision-making based on health indicators and outcomes
-
- Start date: September 2015
 - End date: June 2021
 - Degree or qualification: Medical doctor - Degree in Medicine and Surgery
 - Institution: Universitat Autònoma de Barcelona (UAB)
 - Country: Spain
 - Subject / Skills: Training and professional qualification as physician

1. Beatriz García Revilla, Marta Murga de la Fuente, Jorge Calderón Parra, Andrea Gutiérrez Villanueva, María Luisa Martín Jiménez, Elena de la Torre Martí, **Gerard Ronda Roca**, Elena Muñoz Rubio. Beneficio De La Terapia Combinada Vs Monoterapia En Pacientes Inmunodeprimidos Con Escasa Respuesta Vacunal Frente Al Sars-Cov-2. Revista Clínica Española. Volume 223, Supplement 2,2023,Pages S6-S7,ISSN 0014 - 2565. [https://doi.org/10.1016/S0014-2565\(23\)00210-2](https://doi.org/10.1016/S0014-2565(23)00210-2).
2. **Ronda-Roca Gerard**, Sancho-López Aránzazu, Ruiz-Antorán Belén, Montero-Hernández Esther, San Martín-Espinosa Alicia. A fatal outcome due to a continuous dosage of gentamicin: a case report. Adverse Drug Reaction Bulletin 344(1): p 1335-1338, February 2024. | DOI: 10.1097/FAD.0000000000000072
3. Calderón-Parra J, Gutiérrez-Villanueva A, **Ronda-Roca G**, Martín-Jiménez ML, de la Torre H, Ródenas-Baquero M, Paniura-Pinedo M, Lozano-Llano C, Pintos-Pascual I, Fernández-Cruz A, Ramos-Martínez A, Muñoz-Rubio E. Efficacy and safety of antiviral plus anti-spike monoclonal antibody combination therapy vs. monotherapy for high-risk immunocompromised patients with mild-to-moderate SARS-CoV2 infection during the Omicron era: A prospective cohort study. Int J Antimicrob Agents. 2024 Mar;63(3):107095. doi: 10.1016/j.ijantimicag.2024.107095. Epub 2024 Jan 18. PMID: 38244814.
4. Supervía A, Córdoba F, Ruíz Antorán B, Martín Pérez B, Martínez Baladrón A, Urdangarín A, Ferrer Dufol A y **Grupo de Trabajo EPITOX**. Registro EPITOX de intoxicaciones en España. Año 2024. Rev Esp Urg Emerg. 2025;4:210–7
5. **Ronda-Roca G**, Caballero-Bermejo AF, Cantillana-Barrenas J, Ruiz-Antorán B. First case reports of intentional Imepitoin overdose in humans: A case of two patients. Toxicol Rep. 2025 Jul 28;15:102098. doi: 10.1016/j.toxrep.2025.102098. PMID: 40792005; PMCID: PMC12337012.
6. Martínez-De Antonio E, **Ronda-Roca G**, Navarro-Matilla B, de Laiglesia-Lorenzo A, Payares-Herrera C. Clinical Case Report: A 65-Year-Old Presenting with Disseminated Intravascular Coagulation as a Rituximab Infusional Reaction. Semin Thromb Hemost. 2025 Nov 10. doi: 10.1055/a-2731-6736. Epub ahead of print. PMID: 41213608
7. **Ronda-Roca G**, Porcel-Maleno J, Lobo-Palomar M, Centeno-Soto G, Ruiz-Casado A, Ruiz-Antorán B. Impact of Thiazides and Fluoropyrimidines Interaction on Myelotoxicity and Other Adverse Events in Real-World Practice: A Retrospective Cohort Study. Cancer Med. 2026 Mar;15(3):e71650. doi: 10.1002/cam4.71650. PMID: 41755543; PMCID: PMC12946645.

Projects

Current Research Projects

1. Retrospective cohort study to assess the increased risk of myelotoxicity associated with the combined use of fluoropyrimidines and thiazides. Protocol and information available at: <https://catalogues.ema.europa.eu/node/4082/administrative-details> (Final results pending publication).
2. Registry of intoxications in the Emergency Department of Hospital Universitari Puerta de Hierro Majadahonda. EPITOX Registry.
3. Experience in the implementation of a protocol for access to medicines under special situations, including general principles and case-based practice within a Clinical Pharmacology Department.
4. A scoping review of the shared decision-making process in patients diagnosed with non-curative colorectal cancer:
A protocol for a systematic review. Protocol available at: <https://osf.io/nkqe4>.
5. Case-control study to evaluate the risk of agranulocytosis and neutropenia associated with the concomitant use of metamizole and chemotherapy regimens based on fluoropyrimidines and oxaliplatin. Protocol and information available at: <https://catalogues.ema.europa.eu/node/4837/administrative-details>

Participation in Clinical Trials

1. Efficacy and safety of fecal microbiota transplantation for recurrent urinary tract infections in women. September 2022 – April 2025. Role: Subinvestigator.
2. A randomized, double-blind, placebo-controlled Phase 3 study of VE303 for the prevention of recurrent *Clostridioides difficile* infection: *RESTORATIVE 303 study*. November 2024 – September 2025. Role: Subinvestigator
3. A multicenter, randomized, double-blind, placebo-controlled 52-week maintenance study and open-label extension evaluating the efficacy and safety of risankizumab in subjects with ulcerative colitis. March 2025 – September 2025. Role: Subinvestigator
4. A Phase 3, randomized, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of guselkumab in participants with fistulizing perianal Crohn's disease. *FUZION CD*. March 2025 – September 2025. Role: Subinvestigator
5. A Phase 3, randomized, double-blind, placebo-controlled program to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. *MK-7240*. March 2025 – September 2025. Role: Subinvestigator
6. A Phase III, multicenter, double-blind, placebo-controlled study to assess the efficacy and safety of induction therapy with RO7790121 in patients with moderately to severely active ulcerative colitis. March 2025 – September 2025. Role: Subinvestigator
7. Randomized controlled clinical trial of fecal microbiota transplantation compared with standard treatment in recurrent acute cholangitis (COLANBIOTA). Role: Subinvestigator

Memberships

- **Spanish Society of Clinical Pharmacology**
- **Catalan Society of Pharmacology**
- **European Association for Clinical Pharmacology and Therapeutics (EACPT)**
 - Member of the *Early-Career Clinical Pharmacologists Working Group*

Other Relevant Information